What's Happening?
bioAffinity Technologies, a biotechnology company specializing in noninvasive diagnostics and early cancer detection, reported a significant increase in sales for its CyPath® Lung diagnostic test. In April 2026, unit sales rose nearly 300% compared to
the same month in 2025, marking a record high for a single month. This growth reflects a trend of accelerating adoption and expanding clinical use of the test, which aids in diagnosing lung cancer. The company attributes this success to increased physician adoption and the test's ability to support lung cancer risk stratification and pulmonary nodule management. CyPath® Lung uses advanced flow cytometry and artificial intelligence to identify cancer-related cells in patient sputum, offering a noninvasive alternative to traditional diagnostic methods.
Why It's Important?
The surge in CyPath® Lung sales highlights a growing demand for noninvasive diagnostic tools in the medical community. This trend is significant as it addresses a critical gap in lung cancer diagnosis, particularly for patients with indeterminate pulmonary nodules. The test's ability to detect lung cancer at an early, more treatable stage could lead to better patient outcomes and reduce the need for invasive procedures. As the number of patients undergoing low-dose CT screenings increases, the demand for accurate, noninvasive diagnostic options is likely to grow. bioAffinity Technologies' success with CyPath® Lung underscores the potential for innovative diagnostic technologies to transform cancer risk assessment and management.
What's Next?
bioAffinity Technologies plans to continue expanding the clinical impact of CyPath® Lung by conducting a large-scale longitudinal clinical study to generate additional validation data. The company is also exploring broader applications of the test, such as monitoring lung cancer survivors post-treatment. Additionally, bioAffinity is developing diagnostic tests for other lung diseases, including asthma and COPD, which could further enhance personalized treatment options. The company's focus on expanding its commercial strategy and increasing physician education suggests a commitment to maintaining its growth trajectory and addressing unmet clinical needs in lung cancer diagnostics.
